A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
about
Advances in Lipidomics for Cancer Biomarkers DiscoveryThe glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation.Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.
P2860
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A decade of pharmacogenomics r ...... l cancer: a systematic review.
@en
type
label
A decade of pharmacogenomics r ...... l cancer: a systematic review.
@en
prefLabel
A decade of pharmacogenomics r ...... l cancer: a systematic review.
@en
P2860
P50
P1476
A decade of pharmacogenomics r ...... l cancer: a systematic review.
@en
P2093
Hans Gelderblom
P2860
P304
P356
10.1586/14737159.2016.1148601
P577
2016-02-03T00:00:00Z